Last reviewed · How we verify
COVID-19 exposure
COVID-19 exposure is a Biologic drug developed by Barts & The London NHS Trust. It is currently in Phase 2 development for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
This drug aims to stimulate the immune system to fight COVID-19 infection.
This drug aims to stimulate the immune system to fight COVID-19 infection. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | COVID-19 exposure |
|---|---|
| Sponsor | Barts & The London NHS Trust |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It does this by activating immune cells to produce a strong response against the virus, helping to prevent severe illness and reduce the risk of hospitalization.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19 (NA)
- Bright Light Therapy for Post-COVID-19 Fatigue (NA)
- Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 (PHASE2)
- Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (NA)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Viral Infections in Healthy and Immunocompromised Hosts
- RESCCUE4 - Group CBT for Social Anxiety in Adolescents (NA)
- Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-19 exposure CI brief — competitive landscape report
- COVID-19 exposure updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI
Frequently asked questions about COVID-19 exposure
What is COVID-19 exposure?
How does COVID-19 exposure work?
What is COVID-19 exposure used for?
Who makes COVID-19 exposure?
What development phase is COVID-19 exposure in?
What are the side effects of COVID-19 exposure?
Related
- Manufacturer: Barts & The London NHS Trust — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing